



Clinical trial results:

A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Summary

EudraCT number	2016-001058-16
Trial protocol	SE DK
Global end of trial date	30 September 2021

Results information

Result version number	v1 (current)
This version publication date	28 October 2021
First version publication date	28 October 2021

Trial information

Trial identification

Sponsor protocol code	NLG-LBC-07
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03576443
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Skåne University Hospital
Sponsor organisation address	Gettingevägen 4, Lund, Sweden, 221 85
Public contact	Karin Fjorden, Skåne University Hospital, Department of Oncology, +46 4617 75 20, karin.fjorden@med.lu.se
Scientific contact	Karin Fjorden, Skåne University Hospital, Department of Oncology, +46 4617 75 20, karin.fjorden@med.lu.se

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 December 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 December 2020
Global end of trial reached?	Yes
Global end of trial date	30 September 2021
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of idelalisib in patients with relapsed/refractory diffuse large B-cell lymphoma.

Protection of trial subjects:

The responsible investigator will ensure that this study is conducted in agreement with the declaration of Helsinki, Fortaleza, Brazil, October 2013 and the laws and the regulations of the country. The protocol has been written, and the study will be conducted according to the guidelines for Good Clinical Practice, issued by The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). As a pre-requirement for implementation, the protocol will have to be approved by the local, regional or national Ethical Review Boards according to the existing national and local regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 July 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Sweden: 27
Country: Number of subjects enrolled	Denmark: 9
Worldwide total number of subjects	36
EEA total number of subjects	36

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4
From 65 to 84 years	29

85 years and over	3
-------------------	---

Subject disposition

Recruitment

Recruitment details:

First patient enrolled 07-Jul-2017

Last patient enrolled 22-Apr-2020

Pre-assignment

Screening details:

2. Histologically confirmed diffuse large B-cell lymphoma (DLBCL) , including transformed low grade lymphoma, with either:

- a. Refractory disease
- b. Persistent disease

Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Overall Trial
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	idelalisib
Investigational medicinal product code	
Other name	Zydelig
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg BID p.o. until progression

Number of subjects in period 1	Overall Trial
Started	36
Completed	30
Not completed	6
Physician decision	1
Adverse event, non-fatal	5

Baseline characteristics

Reporting groups

Reporting group title	Overall Trial
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall Trial	Total	
Number of subjects	36	36	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	4	4	
From 65-84 years	29	29	
85 years and over	3	3	
Gender categorical			
Units: Subjects			
Female	25	25	
Male	11	11	

End points

End points reporting groups

Reporting group title	Overall Trial
Reporting group description: -	

Primary: Overall response rate

End point title	Overall response rate ^[1]
End point description:	

End point type	Primary
----------------	---------

End point timeframe:

Response was evaluated at weeks 8, 16, 24 and every 12 weeks thereafter, until 108 weeks after start of therapy

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This is a single arm study. Please refer to the published study

End point values	Overall Trial			
Subject group type	Reporting group			
Number of subjects analysed	36			
Units: subjects	5			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All AEs will be recorded from the time the subject signs informed consent to 28 days after the last dose of study drug.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	CTCAE
Dictionary version	4.03

Reporting groups

Reporting group title	Overall Trial
-----------------------	---------------

Reporting group description: -

Serious adverse events	Overall Trial		
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 36 (50.00%)		
number of deaths (all causes)	26		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Chest pain			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Vomiting			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			

subjects affected / exposed	5 / 36 (13.89%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Dehydration			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Haemolysis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Tumour haemorrhage	Additional description: GI Bleeding		
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Ascites			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash maculo-papular			

subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cytomegalovirus infection reactivation			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Overall Trial		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 36 (97.22%)		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	8 / 36 (22.22%)		
occurrences (all)	8		
Neutropenia			
subjects affected / exposed	6 / 36 (16.67%)		
occurrences (all)	6		
Thrombocytopenia			

subjects affected / exposed occurrences (all)	4 / 36 (11.11%) 4		
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	7 / 36 (19.44%) 7		
Hepatobiliary disorders Transaminases increased subjects affected / exposed occurrences (all)	12 / 36 (33.33%) 12		
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	2 / 36 (5.56%) 2		
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	5 / 36 (13.89%) 5		
Infections and infestations Infection subjects affected / exposed occurrences (all) Cytomegalovirus infection reactivation subjects affected / exposed occurrences (all)	10 / 36 (27.78%) 10 3 / 36 (8.33%) 3		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The trial was terminated prematurely after recruiting half of the originally planned number of patients due to futility in reaching the primary end-point

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/34435356>